FDA approves new prostate cancer drug

Prostate cancer is the second leading cause of cancer death among men in the United States.

By
December 30, 2008 12:24

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user uxperience almost completely free of ads
  • Access to our Premium Section and our monthly magazine to learn Hebrew, Ivrit
  • Content from the award-winning Jerusalem Repor
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Federal regulators on Monday said they have approved the first new drug to treat prostate cancer in four years. The injectable treatment from privately held Ferring Pharmaceuticals fights the cancer by lowering levels of testosterone, which promotes the growth of tumors in the prostate. Food and Drug Administration officials said older drugs in the same class can actually increase testosterone production before they begin lowering them. In studies on prostate cancer patients, Ferring showed that its drug, degarelix, does not raise testosterone levels. According to the FDA, patients treated with degarelix had testosterone levels comparable to those seen after the testes are removed. "Prostate cancer is the second leading cause of cancer death among men in the United States and there is an ongoing need for additional treatment options," Richard Pazdur, the FDA's cancer drug chief, said in a statement. Prostate drugs in the same class as degarelix include AstraZeneca's Zoladex and Abbott Laboratories' Lupron Depot. Nearly 190,000 men were diagnosed with prostate cancer and 29,000 men died from the disease in 2004, the most recent year for which statistics are available. Ferring Pharmaceuticals is headquartered in Switzerland with US offices in Parsippany, N.J.

Related Content

[illustrative photo]
September 24, 2011
Diabetes may significantly increase risk of dementia

By UNIVERSITY OF MICHIGAN HEALTH SYSTEM